Core Viewpoint - Tonghua Golden Horse has made significant progress in the development of its new chemical drug, Amber Dihydroaminoacridine Tablets, which has completed comprehensive review work and is now in the final review stage, marking it as a noteworthy event in the near term [2] Financial Performance - For the third quarter of 2025, the company reported revenue of 892 million yuan and a net profit attributable to shareholders of 24.96 million yuan [2]

其他常规事件如财务报告发布已基于2025年三季报数据（营收8.92亿元，归母净利润2496.35万元），但 无公开信息提示近期有重大股东大会或产品发布等计划。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 根据通化金马（000766）在投资者互动平台的最新披露，公司研制的化学1类新药琥珀八氢 氨吖啶片已完成综合审评工作，并进入最后审评环节，这一进展可能成为近期值得关注的事件。该信息 由公司于2026年2月12日通过官方渠道确认。 业绩经营情况 ...

Group 1 - The company, Tonghua Golden Horse, has indicated that it will disclose significant information regarding the review of its new drug, Amber Dihydroaminoacridine Tablets, through designated information disclosure media [2] - Investors are advised to pay attention to the company's announcements for updates on the drug's market application review process [2]

（文章来源：每日经济新闻） 每经AI快讯，通化金马（000766.SZ）2月12日在投资者互动平台表示，公司研制的化学1类新药琥珀八 氢氨吖啶片目前已完成综合审评工作，并已按要求提供各专业研究资料，进入最后审评环节，各项工作 进展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 ...

Group 1 - The core point of the article is that Tonghua Golden Horse has completed the comprehensive review of its new chemical drug, Amber Tetrahydroaminoacridine Tablets, and is now in the final review stage [2] - The company has provided all required professional research materials as part of the review process [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

Group 1 - The company has completed the comprehensive review of its new drug, a chemical Class 1 oral medication for Alzheimer's disease, and is currently in the final review stage [2] - The company has provided all required professional research materials as part of the approval process, and all work is progressing normally [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

春回大地，万象启新！2026年2月4日，恰逢立春时节。在国家1类新药琥珀八氢氨吖啶片获批进入倒计时的关键节点，为深化推进集团创新转型，加速集 团北京总部暨北京科创中心的战略落地，大兴区委书记初军威、区长刘洋、副区长安学军等区领导隆重会见金马药业集团董事长张玉富先生一行。 区委书记初军威介绍大兴区产业布局，区长刘洋，副区长安学军陪同参观 双方以春为约，围绕创新药获批后的总部建设、科创中心落地、新药生产及商业化推广、神经领域创新药持续投入和研发、智能医疗生态构建等核心议题 深度磋商，达成全方位共识，为金马药业扎根"中国药谷"、赋能首都医药健康产业高质量发展注入磅礴动能，让合作共赢的信心与春天的朝气一同升腾！ 集团医疗板块总裁、建设板块总裁，研发副总裁、金融副总裁、IT总监陪同调研。 参观北京市大兴区营商服务中心 行程伊始，在区委书记初军威、区长刘洋、副区长安学军等区领导的全程陪同下，集团项目工作组走进大兴区营商服务中心。 初军威书记亲自推介区域发展优势：大兴区立足首都都市圈核心枢纽定位，坐拥临空经济区、自贸区、综保区"三区叠加"的独特政策红利，联动京津冀协 同发展的战略价值凸显。全区锚定生命健康、临空产业、先进制 ...

Core Viewpoint - Tonghua Golden Horse has developed a Class 1 chemical new drug, Amber Dihydroaminoacridine Tablets, primarily for the treatment of mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress reported as normal. Major information regarding the new drug will be disclosed through designated media outlets [2]. Company Summary - The new drug, Amber Dihydroaminoacridine Tablets, is aimed at treating mild to moderate Alzheimer's disease [2]. - The company has completed the comprehensive review process for the new drug and is now in the final review phase [2]. - All progress related to the new drug is reported to be on track, indicating a positive development timeline [2].

Core Viewpoint - The company Tonghua Jinma (000766.SZ) has provided an update on its new drug development, specifically the chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, which is primarily aimed at treating mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress being normal. The company will disclose significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]. Group 1 - The new drug Amber Dihydroaminoacridine Tablets is intended for the treatment of mild to moderate Alzheimer's disease [2]. - The drug has completed comprehensive review work and is now in the final review stage [2]. - The company assures that all progress related to the new drug is normal [2].

正是由于琥珀八氢氨吖啶片让通化金马拥有了创新药概念，因此其相关进展情况也备受机构投资者关 注。 通化金马(000766)12月15日披露的投资者关系活动记录表显示，公司于近日接待了申万宏源证券和建信 基金的调研。 通化金马主要从事医药产品的研发、生产与销售，公司目前形成了本部、圣泰生物、永康制药和源首生 物等组成的业务单元集群。公司及子公司产品涵盖抗肿瘤、微生物、心脑血管、清热解毒、消化系统、 骨骼肌肉系统、妇科系统、神经系统等多个领域。 此前，通化金马曾于2024年8月29日晚公告，公司于近日收到国家药品监督管理局签发的琥珀八氢氨吖 啶片上市申请的《受理通知书》。琥珀八氢氨吖啶片是具备完全自主知识产权的小分子化学I.I类国家级 新药，用于治疗轻中度阿尔茨海默病，于2007年11月获得I期临床试验批件，2015年8月获得III期临床试 验批件，并于2017年8月至2023年9月完成Ⅲ期临床试验并揭盲。 通化金马在2025年半年报中介绍，目前公司正严格按照国家药品监督管理局药品审评中心有关法律、法 规及指导原则开展新药上市申请相关工作。 "当前，琥珀八氢氨吖啶片已经完成专业审评的各项工作，正在进行最终的综合审评 ...